Introduction
============

Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disorder distinguished by non-normalizing airflow limitation.[@b1-copd-8-221] Although pulmonary derangements are the primary diagnostic and clinical manifestations, COPD is increasingly being recognized as a multisystem disorder with protean features.[@b2-copd-8-221]--[@b6-copd-8-221]

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines state that the primary goals of COPD management are to reduce the clinical manifestations of COPD by relieving symptoms, improving exercise tolerance and health status, and diminishing risk by reducing mortality, preventing disease progression, and decreasing exacerbations.[@b1-copd-8-221] The pharmacologic armamentarium for the treatment of COPD includes methylxanthines; corticosteroids; supplemental oxygen; and inhalable short- and long-acting beta agonists, anticholinergic bronchodilators, and aerosolized corticosteroids, alone or in various combinations. Most of the original inhalers utilized chlorofluorocarbon (CFC) propellants that have been shown to be environmentally deleterious. Recent innovations have developed novel devices for the delivery of respiratory medications. This review will examine the reasons for the development of new respiratory delivery systems, the design of the Respimat® Soft Mist Inhaler™ (SMI) (Boehringer Ingelheim, Ingelheim, Germany), and its use to administer the combination of albuterol (AB) and ipratropium bromide (IB) to patients with COPD. ("Albuterol" is the US term for salbutamol and the two terms are used interchangeably throughout this review.)

Review methodology
==================

A search of the literature in the PubMed database using the keywords "COPD," "albuterol," "ipratropium bromide," and "Respimat® Soft Mist Inhaler™" was undertaken. Identified citations and pertinent references within the citations were also included in the review. References were reviewed and the most clinically relevant sources are cited. Studies were not graded by criteria defined a priori.

History of chlorofluorocarbons and their environmental impact
=============================================================

In 1928, Thomas Midgley, Albert Henne, and Robert McNary invented Freon, a CFC, to replace the toxic hazardous chemicals such as ammonia, methyl chloride, and sulfur dioxide that were being used as refrigerants at that time.[@b7-copd-8-221] Perhaps the first public demonstration of CFC inhalation occurred in 1928 at the American Chemical Society, when Thomas Midgley inhaled a full breath of Freon and blew it onto a candle, extinguishing the flame, to demonstrate that Freon was both safe and nonflammable.[@b8-copd-8-221] By the 1950s, CFCs were being used as home refrigerants, cleaning and industrial solvents, foam-blowing agents, and aerosol propellants.[@b9-copd-8-221] In 1956, Riker Laboratories manufactured the first CFC-pressurized metered-dose inhaler (pMDI) for delivering aerosolized medications.

However, in 1971, Lovelock found traces of CFC-11 in the atmosphere.[@b10-copd-8-221] Studies of CFCs released into the environment showed that they rise from the troposphere (lower atmosphere) to the stratosphere (upper atmosphere). Due to strong bonds between carbon, chlorine, and fluorine, CFCs are resistant to degradation by environmental physical and biological systems and may remain in the stratosphere for over half a century.[@b11-copd-8-221],[@b12-copd-8-221] Contemporaneously, observational studies revealed an enlarging hole in the ozone layer above Antarctica ([Figure 1](#f1-copd-8-221){ref-type="fig"}).[@b13-copd-8-221],[@b14-copd-8-221] These seemingly disparate observations were linked in 1974 when Molina and Rowland[@b16-copd-8-221] theorized that chlorine radicals generated by the photolytic degradation of CFCs could cause the catalytic degradation of stratospheric ozone. Further investigations confirmed that CFCs are eventually degraded by solar radiation and release chlorine radicals that react with atmospheric ozone.[@b17-copd-8-221] One chlorine radical is estimated to eliminate up to 100,000 ozone molecules.[@b18-copd-8-221] Molina and Rowland received the 1995 Nobel Prize for attributing the shrinking ozone layer to the accumulation of CFCs in the stratosphere.

Stratospheric ozone protects humans by absorbing ultraviolet B radiation. Excess ultraviolet B may increase the risk of sunburn, skin cancer, photokeratitis, cataracts, and cause immune suppression as well as harm phytoplankton and plants.[@b19-copd-8-221]--[@b21-copd-8-221] A 1% reduction in stratospheric ozone is estimated to cause a 3% increase in the incidence of nonmelanoma skin cancer.[@b22-copd-8-221]

By 1978, the Environmental Protection Agency, in collaboration with the US Food and Drug Administration, prohibited CFC propellants in all self-pressurized containers except pMDIs. By 1987, 27 countries including the USA had signed the *Montreal Protocol on Substances that Deplete the Ozone Layer* (hereafter the *Montreal Protocol*) and agreed to a 50% reduction in the use of ozone-depleting substances (ODSs) by 1998. The number of countries signing the *Montreal Protocol* subsequently increased to 188 and it was amended to call for developed countries to cease use of ODSs by 1996. Through inventive engineering, legislation, and international funding, the *Montreal Protocol* has led to the reduction and almost complete elimination of ODSs through the collaboration of governments, industry, scientists, and environmentalists.[@b23-copd-8-221] Another benefit of the *Montreal Protocol* is the mitigation of CFCs' effect on climate change.[@b24-copd-8-221],[@b25-copd-8-221] Despite the realization of the harmful effects of CFCs and their expeditious elimination through international cooperation, it is projected that the stratospheric ozone layer will not recover until at least 2060.[@b23-copd-8-221]

Alternatives to CFCs
====================

In preparation for the elimination of CFCs from pMDIs, pharmaceutical companies formed a coalition in 1989 to develop CFC replacements and identified hydrofluoroalkanes (HFAs) (HFA-134a and HFA-227a) as propellants that do not deplete ozone. These compounds were prepared in two formulations: HFA suspension and HFA solution aerosols.[@b26-copd-8-221] HFAs are composed of carbon, fluorine, and hydrogen atoms and do not contain chlorine. Two issues developed during the transition from CFC to HFA propellants: (1) seal leaks occurred because the seal materials used in CFC-pMDIs were not compatible with HFAs and (2) differences in thermodynamic properties of CFCs and HFAs led to solubility problems. In CFC-pMDIs, surfactants (oleic acid, lecithin, and sorbitan trioleate) were used to enhance the stability of suspensions of micronized particles but surfactants were insoluble in HFAs, causing particles to adhere to the valve and container surfaces and clog the egress aperture. These effects worsened with longer storage time, affected dose delivery, and required changes in co-solvents, gas flow, aperture of the exit, volume within the expansion chamber, and size and velocity of the drug particle-propellant droplets.[@b17-copd-8-221],[@b27-copd-8-221],[@b28-copd-8-221] Once these issues were resolved, a reformulated AB with HFA propellant was approved in 1996. By 2005, more than one brand of HFA-AB was available and the US Food and Drug Administration ruled that CFC-containing AB pMDIs were no longer essential and would be prohibited in the USA after 2008. On December 31, 2008, CFC-containing pMDIs were banned in the USA and replaced by HFA-based inhalers that cost as much as threefold more;[@b29-copd-8-221] for other drugs, replacement HFAs were launched at the same price.

Alternatives to pMDIs
=====================

In addition to HFA-based inhalers to replace CFC-containing pMDIs, other alternative delivery systems for respiratory medications have been developed.[@b30-copd-8-221] These replacements include dry powder inhalers and small aerosol-generating devices.[@b31-copd-8-221] Potential techniques to create aerosols have included piezoelectric vibration, extrusion through small apertures, electrohydrodynamic effect, and collision of solution jets.[@b31-copd-8-221] The remainder of this review will concentrate on the development and use of this last technique to deliver a combination of AB and IB.

Respimat SMI design, development, and operation
===============================================

The Respimat SMI is an alternative to pMDIs that forces a drug solution through a series of channels leading to two nozzles that focus two fluid jets into a precisely calculated convergence producing a vapor of inhalable droplets.[@b31-copd-8-221],[@b32-copd-8-221] The initial prototype for this device was constructed from a syringe containing a solution and a metal pump body ([Figure 2](#f2-copd-8-221){ref-type="fig"}). By pushing a lever, a measured amount of fluid was withdrawn from the syringe and a spring compressed to store mechanical energy. This energy was realized when the spring was released, pushing a piston that forced the solution through small channels forming two fluid jets that collided and produced a vapor with a mean particle mass size between 1 and 5 micrometers. Although this prototype design was effective in producing an aerosol with inhalable particles sized to be deposited in the lower airway, the fabrication of nozzles by puncture of a steel disc did not reliably create the precise angle of convergence required to produce a respirable vapor. Therefore, a novel nozzle configuration was designed from silicon-glass material with a series of channels leading to two apertures that aimed the two jets into convergent paths at a reliably reproducible angle to produce the desired aerosol. This silicon-glass configuration was constructed using dependable fabrication methods developed by the microelectronics industry. Using photolithographic techniques, a precise fluid path is etched into a silicon substrate that is then enclosed by two glass plates and sealed by anodic bonding to create the "uniblock" device that produces the aerosolized vapor[@b31-copd-8-221] ([Figure 3](#f3-copd-8-221){ref-type="fig"}).

Subsequent modifications of the delivery device included reducing the energy required to activate the piston to a level that could be easily produced by an individual and storing the solution within a double-walled, plastic, collapsible bag within an aluminum canister. Further engineering design and manufacturing innovations were required to scale manufacture of these devices from prototypes to mass production.[@b31-copd-8-221]

The optimal aerodynamic diameter for deposition in the lower airway is between 1 and 5 micrometers; particles \< 1 micrometers tend to be inhaled and exhaled without deposition and particles \> 5 micrometers tend to be deposited in the upper airway. Approximately 75% of the aerosolized particles produced by the Respimat SMI have a mean aerodynamic diameter ≤ 5.8 micrometers and ≤3%--5% of the particles have a diameter \< 1 micrometers.[@b32-copd-8-221],[@b33-copd-8-221]

The efficiency of aerosolized medication delivery to the lower airway is highly affected by the deposition of medication in the inhaler and posterior pharynx that occurs due to spray momentum including aerosol ballistic effects and turbulent dispersion.[@b34-copd-8-221]--[@b38-copd-8-221] Coordination of device activation and inhalation is theoretically more critical for devices that produce particles with greater velocity and for shorter duration. It is believed that improved lower airway drug delivery is achieved when smaller particles are generated with less momentum and longer aerosol duration.[@b39-copd-8-221] Hochrainer et al[@b40-copd-8-221] measured the spray velocity 10 cm from the device nozzle for ipratropium/fenoterol delivered by CFC-pMDI, HFA-pMDI, and Respimat SMI devices to be 5.6, 2.4, and 0.8 m/s, respectively. They also determined the spray duration by video recording to be 0.15, 0.21, and 1.45 s, respectively.[@b40-copd-8-221] Thus, the Respimat SMI device produces a slower moving spray that remains aerosolized for 7--10 fold longer than pMDI's. The slower velocity of the particles that emerge from the Respimat SMI should theoretically improve entrainment of the particles during inhalation, increase delivery to the lower airway, and reduce upper airway deposition. In addition, the longer duration of the particle mist generated by the Respimat SMI may increase the window for successful medication inhalation. Scintigraphic studies demonstrate greater lung and less oropharyngeal deposition with Respimat® Soft Mist Inhaler™ compared with dry powder inhalers and pMDIs with and without spacers.[@b41-copd-8-221]--[@b45-copd-8-221] In studies of healthy volunteers, Newman et al[@b42-copd-8-221],[@b43-copd-8-221] showed that the proportion of either flunisolide or fenoterol deposited in the lungs by Respimat® Soft Mist Inhaler™ ranged from 39.2--44.6% whereas only 26.2--39.9% was deposited in the oropharynx. In contrast, lung deposition with a pMDI alone ranged from 11.0--15.3% and with a pMDI with a spacer from 9.9--28.0%.[@b42-copd-8-221]--[@b43-copd-8-221] In patients with asthma, the Respimat® Soft Mist Inhaler™ deposited 51.6% of inhaled budesonide in the lungs and 19.3% in the oropharynx compared with 28.5% and 49.3%, respectively, with the Turbohaler® and a fast inhalation flow rate.[@b44-copd-8-221] Lung deposition for fenoterol hydrobromide/ipratropium bromide delivered by Respimat® Soft Mist Inhaler™ in patients with COPD was 37% before training and 53% after training.[@b45-copd-8-221] In contrast, for the same patients, lung deposition was only 21% when the same medication was delivered by HFA-pMDI before or after training.[@b45-copd-8-221]

To use the Respimat SMI, the transparent base is removed, the medication-containing cartridge is inserted, and the base replaced. After loading, the device must be activated and primed to remove air from the solution flow path prior to use. Four activations are required to insure priming of a new device. If the device is not used for more than 3 days, it must be activated once to re-prime it; if it is not used for 21 days, it must be primed as if it were a new device.[@b31-copd-8-221] To activate the device, the base is twisted half a turn--180°--until it clicks. This motion turns a helical cam gear that compresses and loads the spring and moves a capillary tube with a one-way valve into the solution cartridge, pulling fluid into the dosing chamber ([Figure 3](#f3-copd-8-221){ref-type="fig"}). By pressing the dose-release button, the patient releases the spring, which pushes the capillary tube toward the uniblock, closing the one-way valve and turning the capillary tube into a piston that forces the solution through the uniblock. The solution flows through the microchannels and diverges into two mirror-image exit nozzles to form two symmetric jets that converge at a precise angle of impact, producing an inhalable particle vapor that exits the device.

The Respimat SMI has a dose counter that shows the approximate number of remaining activations and turns red when approximately 1 week of medication remains in the canister. A locking mechanism inactivates the device after the maximal number of activations has been reached to prevent continued use of the device after the medication solution has been depleted or reached a level of incomplete filling of the dosing chamber. The canisters are colored for specific medications and the base is clear so that the canister color is easily visualized. The dose indicator and canister can be configured to provide 60 or 120 activations, depending on the medication and its dosing regimen.[@b31-copd-8-221]

In comparison with HFA-pMDIs, the Respimat SMI requires "cocking" to load the chamber and compressing of the spring prior to activation by pressing the dose-release button, whereas pMDIs simply require pressing the drug canister into the mouthpiece for activation and drug delivery. Although most guidelines recommend the use of a spacer device with pMDIs, the use of a spacer with the Respimat SMI is not required.[@b46-copd-8-221]

Clinical trials
===============

The efficacy and safety of IB/AB (20/100 mcg) Respimat (Combivent Respimat®), IB/AB (36 mcg/206 mcg) metered-dose inhaler (MDI) (Combivent® MDI), or IB (20 mcg) Respimat (Ipratropium Respimat®) were compared in an international, multicenter, double-blind double-dummy, 12-week, parallel-group, active-controlled study of 1480 patients with moderate to severe COPD.[@b47-copd-8-221] Comparing the forced expiratory volume in 1 second (FEV~1~) area under the curve (AUC) at baseline to day 85, this study showed:

-   equivalent efficacy (non-inferiority) in the change in FEV~1~ AUC 0--6 hours for Combivent Respimat versus Combivent MDI, −3 mL (95% confidence interval \[CI\], −22, 15) (the change in FEV~1~ AUC for the periods 0--4 and 4--6 hours were also the same)

-   equivalent efficacy (non-inferiority) in the change in FEV~1~ AUC 4--6 hours for Combivent Respimat versus Ipratropium Respimat, −17 mL (95% CI, −39, 5) (the change in FEV~1~ AUC for the period 0--6 hours was also equivalent)

-   greater change in FEV~1~ AUC 0--4 hours for Combivent Respimat versus Ipratropium Respimat, 47 mL (95% CI, 28, 66).

The median time to response onset and time of maximal response were also equivalent for the three treatments. The peak FEV~1~, maximal change in FEV~1~, and peak forced vital capacity (FVC) were equivalent for Combivent Respimat and Combivent MDI and greater than Ipratropium Respimat at all time points. There were no significant differences in adverse events or vital signs in the three groups. The frequency of COPD exacerbations, 10.4%--14.8%, was also equivalent.

Kilfeather et al[@b48-copd-8-221] compared IB and fenoterol hydrobromide (FEN) in varying combinations and delivered by either Respimat or pMDI in 892 subjects with moderate to severe COPD during a 12-week trial. Patients were randomized to IB 10 mcg/FEN 25 mcg (Respimat SMI 10/25, one actuation four times per day \[qid\]), IB 20 mcg/FEN 50 mcg (Respimat SMI 20/50, one actuation qid), Respimat SMI placebo (Respimat SMI placebo, one actuation qid), IB 20 mcg/FEN 50 mcg (MDI 40/100, two actuations qid), and MDI placebo (MDI placebo, two actuations qid). The primary endpoint was the change in FEV~1~ AUC 0--1 hour prior to dosing compared with the first 60 minutes after dosing on day 85. Respimat SMI 20/50 but not Respimat 10/25 was not inferior to MDI 40/100 and both Respimat SMI doses produced significantly greater increases than Respimat SMI placebo. Interestingly, the rate of COPD exacerbations among the subjects with serious adverse events was greater in the treatment groups than in the placebo groups: Respimat SMI 10/25 (2.3%), Respimat SMI 20/50 (4.9%), Respimat SMI placebo (0.9%), MDI 40/100 (2.7%), and MDI placebo (0.9%). The overall rates of COPD exacerbations were: Respimat SMI 10/25 (20.3%), Respimat SMI 20/50 (26.8%), Respimat SMI placebo (19.3%), MDI 40/100 (20.9%), and MDI placebo (17.9%). Other reported adverse events occurred at similar rates across all groups. This study concluded that the use of the Respimat SMI delivery system produced the same bronchodilator effect as twice the dose of IB and FEN delivered by a CFC-pMDI system with similar side effects.

Iacono et al[@b49-copd-8-221] studied the efficacy and safety of cumulative doses of IB delivered by Respimat SMI (10 or 20 mcg per actuation) or pMDI (20 mcg per actuation) in a three-period crossover trial. The primary endpoint was the increase from baseline in the average absolute FEV~1~ between 45 and 245 minutes after the initial inhalation. Respimat SMI 10 or 20 had similar effects on the primary endpoint that were greater than those produced by pMDI 20. The change in FEV~1~ (in liters) 1 hour and thereafter following the last inhalation were equivalent. Adverse events and changes in vital signs were equivalent across all the groups. This study concluded that the Respimat SMI delivery system produced the same short-term bronchodilator effect as twice the cumulative dose of IB delivered by CFC-pMDI with a similar safety profile.

Ram et al[@b50-copd-8-221] performed a systematic review of seven randomized controlled clinical trials comparing Respimat SMI with other devices delivering aerosolized medications in patients with COPD, published before September 2010, and concluded that the Respimat inhaler does not provide any significant clinical benefit when compared with other handheld delivery devices. They found no differences in trough FEV~1~, trough FVC, peak FEV~1~, peak FVC, morning peak expiratory flow rate (PEFR), evening PEFR, exacerbations, or adverse events. The trials were of varying duration, used different endpoints, and studied various medications or combinations of medications at different concentrations including fenoterol plus ipratropium, ipratropium alone, tiotropium, ipratropium plus fenoterol, and ipratropium plus AB.

Patient response and perceptions
================================

Besides physiologic efficacy, another critical element in determining the clinical utility of bronchodilator therapy is patients' adherence to treatment; a highly effective medication that is not used has no clinical utility.[@b51-copd-8-221] The factors that influence adherence to bronchodilator management are poorly understood but include patients' attitudes and perceptions about bronchodilators and their delivery devices and patients' experiences and reactions to their use.[@b52-copd-8-221] Further, despite the evidence for differences in physiologic efficacy and deposition patterns, there is no overwhelming evidence to suggest that the type of inhaler device alters clinical outcomes in patients with COPD.[@b53-copd-8-221]--[@b55-copd-8-221] Two assessments of inhaler satisfaction and preference have been developed, the Patient Device Experience Assessment and the Patient Satisfaction and Preference Questionnaire (PASAPQ).[@b56-copd-8-221]--[@b58-copd-8-221] Hodder and Price reviewed studies of patients' experiences with the Respimat SMI and found that the device is well accepted and patients preferred its performance to other respiratory medication delivery devices.[@b59-copd-8-221] In a randomized, open-label, controlled, two-period, crossover study comparing IB/fenoterol delivered by Respimat SMI 20/50 mcg or HFA-pMDI 40/100 mcg in 245 patients with COPD, asthma, or mixed disease and a primary endpoint of inhaler preference, 162/201 (81%) subjects preferred Respimat SMI and 39/201 (19%) preferred HFA-pMDI.[@b60-copd-8-221] At the end of the study, more patients were willing to continue using Respimat SMI (85) than HFA-pMDI (50). The overall satisfaction score was greater for Respimat SMI than for HFA-pMDI and appeared to be due to the subjects' perceptions of performance rather than convenience. Clinical efficacy measured by evening PEFR, rescue inhaler use, and symptom scores was equivalent for the two treatments. In a randomized, parallel-group, double-dummy study comparing budesonide delivered by Respimat SMI (200 or 400 mcg twice daily \[bid\]) and Turbuhaler® (AstraZeneca, London, UK) dry powder inhaler (400 mcg bid) in 153 adults with moderate or severe asthma, subjects' preferences were measured with the PASAPQ.[@b52-copd-8-221] Total PASAPQ scores were 85.5 and 76.9 (*P* \< 0.001) for Respimat SMI and Turbuhaler, respectively, and 112 (74%) subjects preferred Respimat SMI, 26 (17%) preferred Turbuhaler, and 14 (9%) had no preference. Performance scores but not convenience scores were different between the devices. Efficacy and safety data were not included in this report. It remains unknown whether the apparent preference of patients for Respimat SMI translates to increased adherence and better clinical outcomes.

Safety
======

Although the currently reported clinical trials evaluating the AB/IB Respimat SMI have reported no significant differences in adverse events, recent evaluations of tiotropium delivered by Respimat SMI suggest an increased risk of mortality.[@b61-copd-8-221]--[@b63-copd-8-221] Singh et al[@b61-copd-8-221] performed a meta-analysis of placebo-controlled, parallel-group, randomized trials of tiotropium delivered by Respimat SMI in patients with COPD and found an increased risk of mortality, with a relative risk (RR) of 1.52 (95% CI, 1.06, 2.15). The RR appeared dose dependent and was 2.15 (95% CI, 1.03, 4.51) and 1.46 (95% CI, 1.01, 2.10) for tiotropium 10 mg and 5 mg, respectively. At the 5 mg dose, one treatment-related death was estimated to occur for every 124 (95% CI, 52, 5682) COPD patients treated with tiotropium Respimat SMI. Two subsequent reviews found increased odds ratios (ORs) of all-cause mortality with tiotropium Respimat SMI of 1.47 (95% CI, 1.04, 2.08) and 1.51 (95% CI, 1.06, 2.19).[@b62-copd-8-221],[@b63-copd-8-221] Based on this evidence, Jenkins and Beasley[@b64-copd-8-221] concluded that "a recommendation can be made that the 5 and 10 mg preparations of tiotropium Respimat® should not be prescribed in the treatment of COPD."

Several studies have suggested that IB is associated with an increased risk of cardiovascular morbidity and mortality in individuals with COPD.[@b65-copd-8-221]--[@b68-copd-8-221] In a study of over 80,000 veterans, treatment with an anticholinergic within the previous 6 months (\>99% IB and in a fixed-dose combination with AB in 38%) was associated with an increased risk of cardiovascular events.[@b68-copd-8-221] In a large cohort of Canadians with COPD, the rate of cardiac dysrhythmias was increased significantly with initial treatment with short-acting (RR, 1.27; 95% CI, 1.03, 1.57) and long-acting beta agonists (RR, 1.47; 95% CI, 1.01, 2.15) and insignificantly with IB (RR, 1.23; 95% CI, 0.95, 1.57).[@b69-copd-8-221] In a Taiwanese population-based, nested, case-control study of individuals with recently diagnosed COPD, ipratropium was associated with an increased risk of stroke (adjusted OR, 2.02; 95% CI, 1.71, 2.41) and the risk was further increased with concomitant treatment with a short-acting beta agonist (adjusted OR, 2.18; 95% CI, 1.81, 2.62).[@b70-copd-8-221] However, none of these studies examined the Respimat SMI delivery system and most did not analyze fixed combination therapy with AB and IB, so further safety monitoring of combined AB and IB delivered by Respimat SMI is warranted to determine whether this delivery system may alter the safety profile of combined AB and IB treatment in individuals with COPD.

Conclusion
==========

Although the combination of IB and AB has been repackaged in an environmentally friendly, innovative device that is more efficient, requiring half the dose for an equivalent physiologic effect with no apparent significant change in adverse events, the mixture of IB and AB itself is the oldest combination of aerosolized respiratory medications. Current recommendations for the use of AB in patients with COPD are to use short-acting beta agonists on an as-needed basis for symptomatic relief rather than on a fixed dosing schedule. In contrast, it is recommended that IB be used four times daily on a regular basis. These conflicting dosing schedules for AB and IB are at variance with the fixed dosing schedule for the combination of AB and ipratropium in Combivent MDI or Combivent Respimat. The Respimat SMI delivery device is an efficient, well-tolerated system for the delivery of aerosolized AB and IB to patients with COPD that produces equivalent physiologic effects at approximately half the dose delivered by pMDIs. However, the potential advantages of this novel system to deliver a fixed combination of two short-acting medications with different dosing schedules should be balanced by alternative therapeutic options that provide longer-acting, less frequently dosed respiratory medications.[@b71-copd-8-221]

**Disclosure**

The author declares no conflicts of interest in this work.

![Maps of the hole in the Antarctic ozone layer demonstrating its enlargement over time.\
**Note:** Reproduced from Ozone hole through the years \[web page on the Internet\]. Greenbelt MD. Earth Observatory; 2011. Available from: <http://earthobservatory.nasa.gov/IOTD/view.php?id=49040>. Accessed Dec 2012.[@b15-copd-8-221]](copd-8-221Fig1){#f1-copd-8-221}

![Configuration of the prototype for the Respimat® Soft Mist Inhaler™. (Boehringer Ingelheim, Ingelheim, Germany).\
**Note:** Dalby RN, Eicher J, Zierenberg B. Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders. *Med Devices (Auckl)*. 2011;4:145--155.[@b29-copd-8-221]](copd-8-221Fig2){#f2-copd-8-221}

![Internal configuration of the uniblock showing the linear flow channels that direct the medication solution to two symmetric exit ports that focus the solution jets into a precisely configured convergence to produce aerosolized droplets that exit the nozzle outlet.\
**Note:** Reproduced from Dalby RN, Eicher J, Zierenberg B. Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders. *Med Devices (Auckl)*. 2011;4:145--155.[@b29-copd-8-221]](copd-8-221Fig3){#f3-copd-8-221}

![Internal mechanism of the Respimat® Soft Mist Inhaler™. (Boehringer Ingelheim, Ingelheim, Germany).\
**Notes:** To activate the device, the base is twisted 180°, which turns a helical cam gear that compresses and loads the spring and moves a capillary tube with a one-way valve into the solution cartridge, thereby pulling fluid into the dosing chamber. When the dose-release button is pressed, the spring releases, pushing the capillary tube toward the uniblock, shutting the one-way valve, and turning the capillary tube into a piston that forces the solution through the uniblock.Reproduced from Dalby RN, Eicher J, Zierenberg B. Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders. *Med Devices (Auckl)*. 2011;4:145--155.[@b29-copd-8-221]](copd-8-221Fig4){#f4-copd-8-221}
